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Objective: There are a lot of disagreements in the studies on hepatitis B virus (HBV) DNA
polymerase mutation rate associated with nucleos(t)ide analogues (NAs) in treatment-naive
chronic hepatitis B (CHB) patients. This is the ﬁrst study aimed to investigate the prevalence
of  spontaneous HBV resistance mutations in Central China.
Methods: This study included treatment-naive patients with CHB from June 2012 to May
2015  receiving care at the Institute of Liver Disease in Central China. All patients completed
a  questionnaire covering different aspects, such as family medical history, course of liver
disease, medication history, alcohol use, among others. Mutations in HBV DNA polymerase
associated with NAs resistance were detected using INNO-LiPA assay.
Results: 269 patients were infected with HBV genotype B (81.4%), C (17.9%), and both B and
C  (0.7%). Mutations in HBV DNA polymerase were detected in 24 patients (8.9%) including
rtM204I/V (n = 6), rtN236T (n = 5), rtM250V (n = 2), rtL180M (n = 2), rtT184G (n = 1), rtM207I (n = 1),
rtS202I (n = 1), rtM204V/I & rtL180M (n = 5), and rtM204I & rtM250V (n = 1).
Conclusion: Spontaneous HBV resistance mutations in HBV DNA polymerase were found
in  treatment-naive patients with CHB in Central China. These ﬁndings suggest that weshould analyze HBV DNA polymerase resistance mutation associated with NAs before giving
antiviral therapy such as lamivudine (LAM), adefovir (ADV), and telbivudine (LdT).
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test, and the normally distributed continuous variables were
analyzed by the Student’s t-test. The nonparametric vari-
ables were analyzed by the Mann–Whitney U-test. All p-values174  b r a z j i n f e c t d 
Introduction
Infection with hepatitis B virus (HBV) can cause severe
diseases such as liver cirrhosis and hepatocellular carci-
noma (HCC), with approximately one million deaths annually
around the world.1 Nucleos(t)ide analogues (NAs), including
lamivudine (LAM), adefovir (ADV), telbivudine (LdT), entecavir
(ETV), and tenofovir (TDF) were recommended by interna-
tional guidelines for suppressing HBV replication, and have
been shown to decrease the rate of complications.2–4
Despite high drug efﬁcacy for inhibiting HBV, one of the
largest obstacles with long-term NAs therapy is the devel-
opment of viral resistance. LAM, used widely as the ﬁrst
NA, has the highest viral resistance rate of 70% after ﬁve
years of therapy.5 ADV and LdT are superior to LAM for their
lower prevalence of viral resistance, while ETV and TDF effec-
tively suppress HBV DNA replication with minimum drug
resistance.6 NAs treatment failure has been linked to muta-
tions at the reverse transcriptase (rt) region of the HBV DNA
polymerase gene, and mutations at individual codons in the
HBV polymerase gene conferring resistance to different NAs.
For example, rtM204V/I pathway is responsible for the resis-
tance to L-NAs, such as LAM, LdT, clevudine (CLD), and ETV.
Also, rtN236T pathway could confer ADV and TDF resistance,
and rtA181T/V pathway could affect LAM, ADV, LdT, and TDF
efﬁcacy.5,7,8
It has been found that natural HBV reverse transcriptase
mutations exist even in treatment-naive patients with CHB
from Europe, Asia, and the Middle East, but the prevalence vary
from 0% to 57%.9–13 This wide range might be caused by dif-
ferent study designs, regions, ethnicities, mutation detection
methods, sample sizes, and so on. Using a systematic review
and meta-analysis, Zhang et al.13 found an 8.0% prevalence of
total and primary mutations among untreated CHB patients in
China, and that Southern China had a little higher pooled total
mutation rate of 8.22% than Northern China 7.55%. There-
fore, it is important to understand the true prevalence of
HBV DNA polymerase mutation analysis among treatment-
naive patients with CHB in different areas of China, because
most of them will be treated with NAs at ﬁrst. To our knowl-
edge, there has been no study in patients of Central China.
The purpose of this study is to determine the prevalence
and clinical characteristics of spontaneous mutations in Cen-
tral Chinese cohort, and focus on clinically signiﬁcant HBV
DNA polymerase associated with NAs resistance mutations
(rtM250V, rtN236T, rtM204V/I, rtS202I, rtA181T/V, rtT184G,
rtL180M, and rtM/V207I) by using the sensitive INNO-LiPA
assay.
Patients  and  methods
Patients
We  performed a prospectively analysis of 269 patients with
CHB of the Institute of Liver Disease, Hubei Provincial Hospi-
tal of Traditional Chinese Medicine, Wuhan who had never
received any anti-HBV treatment with NAs or interferon,
between June 2012 and May 2015. Patients were included 1 6;2  0(2):173–178
according to the following criteria – age 18 years or older, HBV
DNA >100 IU/mL, positive hepatitis B surface antigen, history
of HBV infection for more  than 6 months. Patients co-infected
with HCV, HDV, or HIV were excluded. The diagnosis of hep-
atitis was established by needle biopsy. Liver biopsies were
performed under ultrasound guiding and histological grade (G)
and stage (S) were evaluated. We  collected patients of chronic
HBV infection and divided them into four phases (immune tol-
erant phase, immune clearance phase, low or non-replicative
phase, reactivation phase) by the standard of the Guidelines
for Chronic Hepatitis B in China, version 2010. The informed
consent was obtained from each patient enrolled in the study.
The study protocol conformed to the ethical guidelines of
the Declaration of Helsinki and was approved by the ethics
committee of Hubei Provincial Hospital of Traditional Chinese
Medicine.
Patient  questionnaires
Questionnaires, including questions about family medical
history, HBV infection and treatment history, other disease
history, ethnicity, and drug and alcohol history were com-
pleted by all patients.
General  laboratory  tests
Markers of HBV infection were measured using the com-
mercial kit of electro-chemiluminescence assay (Roche
Diagnostics, Mannheim, Germany). HBV DNA was quantiﬁed
using the Amplicon monitor assay (ABI, California, USA). ALT,
AST, and GGT were determined using the commercial kit of
ultraviolet absorption spectrophotometry assay (Roche Diag-
nostics, Mannheim, Germany).
HBV  polymerase  gene  mutation  and  genotype  by
INNO-LiPA
HBV DNA polymerase mutations and genotypes were mea-
sured using the INNO-LiPA assay kit (Shenzhen, China). This
assay detected mutations at codons 180, 181, 184, 202, 204,
207, 236, 250 of the HBV DNA polymerase gene, with a
reported detection lower bound of 5% of the circulating viral
load.
Statistical  analysis
Results were reported as mean and standard deviation and/or
median and range for continuous variables and percentages
for categorical variables. The categorical data were compared
between groups using the chi-square test or Fisher’s exactwere two-tailed, and p < 0.05 was considered statistically
signiﬁcant. Data analysis was performed using the Statisti-
cal Package for Social Science version 19.0 (SPSS, Chicago,
USA).
b r a z j i n f e c t d i s . 2 0 1 6;2 0(2):173–178 175
Table 1 – Characteristics of patients according to the status of HBeAg.
Characteristics Total cohort (N = 269) HBeAg-positive (n = 66) HBeAg-negative (n = 203) p-Value
Age (y) 41 (23–72) 39 (23–69) 44 (24–72) 0.17
Male gender 201 (74.7%) 51 (77.3%) 159 (78.3%) 0.99
Ethnicity
Han 247 (91.8%) 60 (90.9%) 187 (92.1%) 0.80
Tujia 21 (7.8%) 6 (9.1%) 15 (7.4%) 0.61
Dong 1 (0.4%) 0 (0%) 1 (0.5%)
History of HBV infection (y) 15 (1–40) 11 (1–30) 16 (1–40) <0.05
Family history of
Liver disease 101  (37.5%) 42 (63.6%) 59 (29.1%) <0.01
Liver cancer 32  (11.9%) 6 (9.1%) 26 (12.8%) 0.52
Clinical stage
Immune tolerant phase 21 (7.8%) 21 (31.8%) 0
Immune clearance phase 45 (16.7%) 45 (68.2%) 0
Non-replicative phase 84 (31.2%) 0 84 (41.4%)
Reactivation phase 119 (44.3%) 0 119 (58.6%)
Liver histologic result
<G2/S2 145 (53.9%) 36 (54.5%) 109 (53.7%) 1.00
≥G2/S2 124 (46.1%) 30 (45.5%) 94 (46.3%) 1.00
Laboratory data
ALT (IU/L) 41 (10–1581) 48 (12–1581) 35 (10–385) 0.13
AST (IU/L) 40 (13–586) 45 (13–586) 32 (13–161) 0.09
GGT (IU/L) 40  (8–396) 39 (8–396) 42 (12–394) 0.27
HBV DNA (log IU/mL) 4.9  ± 1.7 6.5 ± 1.4 4.3 ± 0.9 <0.01
DNAP mutation 24  (8.9%) 6 (9.1%) 19 (9.4%) 0.11
HBV genotype
B 219 (81.4%) 45 (68.2%) 174 (85.7%) <0.05
C 48 (17.9%) 21 (31.8%) 27 (13.3%) <0.01
B + C 2 (0.7%) 0 (0%) 2 (1.0%) 1.00
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esults
atient  characteristics
he characteristics of participating patients at baseline are
eported in Table 1. Of the 269 patients, 74.7% (201/269) were
ale with a median age of 41 years. At baseline, 75.5%
203/269) of the patients were HBeAg negative, and the HBV
NA load was 4.9 log IU/mL. Furthermore, 81.4% (219/269),
7.9% (48/269) and 0.7% (2/269) patients were infected with
BV genotype B, C, and B & C, respectively.
HBeAg-positive patients had a shorter median time of
BV infection (p < 0.05), and were signiﬁcantly more  likely to
eport a family history of liver disease (p < 0.01), compared with
BeAg-negative patients. HBeAg-positive patients had signif-
cantly higher baseline HBV DNA loads than HBeAg-negative
p < 0.01). HBeAg-positive patients were more  likely to have
BV genotype C infection than HBeAg-negative (p < 0.01), but,
ontrary to the latter, had higher prevalence rate of HBV geno-
ype B than the former (p < 0.05).revalence  of  HBV  DNA  polymerase  mutations
able 2 lists the characteristics of patients with HBV DNA
olymerase mutations based on INNO-LiPA assay. HBV DNAor median (range).
lutamyl-transferase; DNAP, HBV DNA polymerase.
polymerase mutations were detected in 24 of 269 total patients
(8.9%), including rtM204I/V (n = 6), rtN236T (n = 5), rtM250V
(n = 2), rtL180M (n = 2), rtT184G (n = 1), rtM207I (n = 1), rtS202I
(n = 1), rtM204V/I & rtL180M (n = 5), and rtM204I & rtM250V
(n = 1). Among all the mutations, rtM204V/I ranked ﬁrst with
the highest prevalence of 4.5% (12/269), which is larger than
the prevalence rate of rtL180M, rtN236T, rtM250V, rtT184G,
rtS202I, and rtV207I (2.6%, 1.9%, 1.1%, 0.4%, 0.4%, and 0.4%,
respectively). Of 24 patients with HBV DNA polymerase muta-
tions, 87.5% (21/24) were male, and the median age was 39
years. In addition, the mean HBV DNA load was 4.34 log IU/mL,
and 25.0% (6/24) of the patients were HBeAg positive with HBV
genotype B. Only one HBV C-genotype, and one HBV C + B-
genotype were detected among the 24 treatment-naive CHB
patients for HBV DNA polymerase mutations.
Discussion
The occurrence of viral resistance to NAs is closely related
with amino acid substitutions in HBV reverse transcriptase,
deﬁned as primary and secondary drug resistance mutations.
There are currently eight codons associated with primary
drug resistance to NAs: rtI169T, rtA181T/V, rtT184S/C/G/A,
rtA194T, rtS202G/C/I, rtM204V/I, rtN236T, and rtM250V; and
three codons associated with secondary resistance to NAs:
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Table 2 – Characteristics of patients with HBV DNA polymerase mutations.
Case Sex Age (y) DNAP mutation HBeAg status HBV DNA (log IU/mL) ALT (IU/L) HBV genotype
1 M 54 M204I + M250V Negative 3.83 21 B
2 M 25 M204I Negative 2.81 35 B
3 M 43 L180M + M204V Negative 3.21 75 B
4 M 60 M204I Negative 4.41 26 B
5 M 38 L180M Negative 6.11 261 C
6 F 31 L180M + M204V/I Negative 6.48 19 B
7 M 56 L180M + M204V/I Negative 3.40 22 B
8 M 32 S202I Negative 2.80 20 B
9 M 46 M204I Negative 3.09 114 B
10 M 26 M204I Positive 3.98 51 B
11 M 41 N236T Negative 2.86 33 B
12 M 39 M204I Positive 5.88 177 B
13 M 41 N236T Positive 6.75 144 B
14 M 36 N236T Negative 4.60 30 B
15 M 39 M250V Negative 4.38 136 B
16 M 65 T184G Negative 4.96 80 B
17 F 36 N236T Positive 3.83 18 B
18 F 46 N236T Negative 2.56 70 B
19 M 49 L180M + M204V Negative 3.53 35 B
20 M 41 L180M + M204V/I Negative 5.21 82 B + C
21 M 38 M250V Negative 2.75 89 B
22 M 39 L180M Positive 6.71 71 B
23 M 24 M207I Positive 6.06 58 B
24 M 37 M204V Negative 3.48 50 B
NA pNote:  M, male; F, female; ALT, alanine aminotransferase; DNAP, HBV D
rtL80I, rtV173L and rt180M.7 The primary mutations refer to
the amino acid changes that result in reduced susceptibility to
an antiviral agent. The secondary mutations cause amino acid
substitutions that restore replication function defects result-
ing from primary resistance and may give rise to a low level of
reduced susceptibility.14,15
Currently, mutations associated with HBV drug resistance
are reported to occur in treatment-naive patients with CHB
for any oral anti-HBV therapy.16–29 This might due to both
HBV viral factors and host factors. First, these mutations
occur naturally, because HBV has a high replication rate,
with an estimated production of about 1012 virions/day, and a
high mutational rate of 10−5 to 10−4 substitutions/base/cycle.
Moreover, the HBV reverse transcriptase does not have
a proofreading function to repair incorrectly incorporated
nucleotides.30 Second, a treatment-naive patient might be
infected by a mutant virus derived from a NAs treated patient.
Third, the patient could be unaware of receiving some treat-
ment with direct anti-HBV activity.
This study has conﬁrmed the existence of HBV DNA poly-
merase resistance mutations for NAs in 24 (8.9%) of 269
treatment-naive patients, composed of ﬁve primary drug
resistance mutations (rtT184G, rtS202I, rtM204I/V, rtN236T,
and rtM250V), one secondary resistance mutation (rtL180M),
and one codon mutation that might be baseline polymor-
phisms without any clinical signiﬁcance (rtV207I). Among the
24 mutations, rtM204V/I was the prevailing type with a higher
prevalence of 4.5% (12/269), compared with other codons with
prevalence as low as 2.6% (7/269) of rtL180M, 1.9% (5/269) of
rtN236T, 1.1% (3/269) of rtM250V, 0.4% (1/269) of rtT184G, 0.4%
(1/269) of rtS202I, and 0.4% (1/269) of rtV207I. This means up
to 6.5% treatment-naive patients with CHB would encounterolymerase.
LAM or LdT or ADV or ETV primary treatment failure ini-
tially, because rtM204V/I (YMDD/YIDD) and rtL180M linked
to LAM and ETV resistance, rtM204I accounts for LdT resis-
tance, and rtN236T could confer ADV resistance. Meanwhile,
2.2% (6/269) are multiple resistance mutations including 1.9%
(5/269) rtM204V/I & rtL180M, and 0.4% (1/269) rtM204V/I &
rtM250V. These treatment-naive patients with CHB would
encounter ETV primary treatment failure initially, because the
combination of rtM204V/I, rtL180M and one of the following
mutations – rtM184S/C/G/A, rtS202G/I/C, or rtM250V – would
lead to ETV resistance.7,8,16
To date, the actual prevalence of HBV DNA polymerase
mutations in treatment-naive patients with CHB is unknown,
and the reported prevalence varied from 0% to 57%.9,12,16–29
Such a wide range is likely due to differences in study design,
study population and geography, study method, study sam-
ple size, and whether study patients were treatment-naive.
Previous studies on the prevalence of drug resistance muta-
tions in treatment-naive patients often used less sensitive
methods or included rather small series of patients.9,19 Now
a new sensitive ultra-deep pyrosequencing assay is able to
detect minor viral quasispecies at a level under 1%.21 A sys-
tematic review and meta-analysis from Zhang et al.13 studied
a total of 70 articles including 8156 treatment-naive patients
with CHB in China, 21 articles of which were from Northern
China and 49 from Southern China. They found that South-
ern China had a little higher pooled total mutation rate of
8.22% than Northern China (7.55%), as well as higher pri-
mary  mutation rate of 8.12% versus 7.13%. The HBV variants
known to confer resistance against NAs were detected and
have a frequency of mutations quite comparable to what we
found. In contrast, Nishijima et al.21 reported a relatively
 2 0 1 
h
C
b
s
s
s
s
r
t
d
t
d
l
i
m
k
r
w
m
a
p
n
N
a
v
T
r
t
m
p
s
a
a
s
t
a
o
v
m
t
t
m
A
T
p
b
A
C
T
A
T
A
R
r
1
1
1
1
1
1
1
1
1
1b r a z j i n f e c t d i s .
igh mutation rate of 35.7% in 14 untreated patients with
HB in Japan using ultra-deep pyrosequencing. The difference
etween their studies and our results could be explained by a
maller sample size as well as the different method they used
ince ultra-deep pyrosequencing analysis is much more  sen-
itive than INNO LiPA. Contrary to the above reports, several
tudies from Europe,9 North America19 and Latin America,28
eported that less than 5% primary mutation rate associated
o NAs were found in treatment-naive patients. They used
irect sequencing assay that could potentially underestimate
he true prevalence because of its limited ability to reliably
etect viral subspecies below 20%–25% of the circulating viral
oad.21 Meanwhile, the cohort of patients was predominantly
nfected with HBV genotypes A, D and C which were not com-
on  genotypes in China, especially Central China.
This study has the following advantages. Firstly, to our
nowledge, this is the ﬁrst comprehensive research about
esistance mutations of the HBV polymerase in Central China,
hile all prior studies only focused on a few provinces and
unicipalities of Northern, Southern, and Eastern China such
s Beijing, Shanghai, and Jiangsu.10,17,25,26,29 Secondly, all 269
atients have been required to ﬁnish a detailed question-
aire including questions about whether they accepted prior
A therapy, while the majority of other studies collected and
nalyzed serum for DNA polymerase mutations but did not
alidate whether the patients received treatment for NAs.
hirdly, we  focused on mutations at the reverse transcriptase
egion of the HBV DNA polymerase gene that has been linked
o different NAs treatment failure, while most researches
erely focused on rtM204V/I, since LAM had the highest
revalence of resistance and YMDD mutation was extensively
tudied. Other primary mutations and secondary mutations
ssociated with resistance to NAs did not receive enough
ttention. Lastly, the INNO-LiPA assay in our study is a sen-
itive and speciﬁc assay that can detect subspecies at 5% of
he circulating viral population, while the direct sequencing
ssay is limited by its lower sensitivity that detects mutants
nly if they consist of greater than 20%–25% of the circulating
iral load.12
In conclusion, the prevalence of HBV DNA polymerase
utations associated with NAs resistance was found to be up
o 8.9% of our 269 treatment-naive patients with CHB in Cen-
ral China. The LAM-associated rtM204V/I mutation occurred
ore  frequently than other primary mutations. In China, LAM,
DV, and LdT are commonly used alone or together, ETV and
DF are seldom used. These ﬁndings suggest that HBV DNA
olymerase associated with NAs resistance mutation should
e analyzed before initiating antiviral therapy such as LAM,
DV, and LdT for the patients with CHB.
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